Related references
Note: Only part of the references are listed.A cost-effectiveness analysis of two topical ophthalmic antibiotic solutions indicated for the treatment of bacterial conjunctivitis
C. Waycaster
VALUE IN HEALTH (2008)
The annual cost of bacterial conjunctivitis in the United States: Evidence from an economic modelling approach
A. F. Smith et al.
VALUE IN HEALTH (2008)
Speed of bacterial kill with a fluoroquinolone compared with nonfluoroquinolones: Clinical implications and a review of kinetics of kill studies
Steven J. Lichtenstein et al.
ADVANCES IN THERAPY (2007)
A randomised controlled trial of management strategies for acute infective conjunctivitis in general practice
Hazel A. Everitt et al.
BMJ-BRITISH MEDICAL JOURNAL (2006)
Clinical safety of moxifloxacin ophthalmic solution 0.5% (VIGAMOX®) in pediatric and nonpediatric patients with bacterial conjunctivitis
LH Silver et al.
SURVEY OF OPHTHALMOLOGY (2005)
An ophthalmologist's guide to understanding antibiotic susceptibility and minimum inhibitory concentration data
RP Kowalski et al.
OPHTHALMOLOGY (2005)
Evaluation of moxifloxacin, ciprofloxacin, gatifloxacin, ofloxacin, and levofloxacin concentrations in human conjunctival tissue
RS Wagner et al.
ARCHIVES OF OPHTHALMOLOGY (2005)
Fluoroquinolone resistance in ophthalmology and the potential role for newer ophthalmic fluoroquinolones
DG Hwang
SURVEY OF OPHTHALMOLOGY (2004)
An outbreak of conjunctivitis due to atypical streptococcus pneumoniae
M Martin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
A phase III clinical trial of 0.5% levofloxacin ophthalmic solution versus 0.3% ofloxacin ophthalmic solution for the treatment of bacterial conjunctivitis
IR Schwab et al.
OPHTHALMOLOGY (2003)
Share Paper
